MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- ALEMBIC - MYLAN (US)
ALEMBIC vs MYLAN (US) - Comparison Results
ALEMBIC Change
Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 ALEMBIC  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALEMBIC Mar-18 |
MYLAN Dec-18 |
ALEMBIC/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 72 | 3,521 | - | |
| Low | Rs | 34 | 1,938 | - | |
| Sales per share (Unadj.) | Rs | 4.7 | 1,620.4 | - | |
| Earnings per share (Unadj.) | Rs | 6.1 | 44.0 | - | |
| Cash flow per share (Unadj.) | Rs | 6.2 | 347.4 | - | |
| Dividends per share (Unadj.) | Rs | 0.20 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 40.7 | 1,752.9 | - | |
| Shares outstanding (eoy) | m | 267.03 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 11.3 | 1.7 | 668.6% | |
| Avg P/E ratio | x | 8.7 | 62.0 | 14.0% | |
| P/CF ratio (eoy) | x | 8.5 | 7.9 | 107.9% | |
| Price / Book Value ratio | x | 1.3 | 1.6 | 83.6% | |
| Dividend payout | % | 3.3 | 0 | - | |
| Avg Mkt Cap | Rs m | 14,139 | 1,404,514 | 1.0% | |
| No. of employees | `000 | NA | 35.0 | 0.0% | |
| Total wages/salary | Rs m | 207 | 0 | - | |
| Avg. sales/employee | Rs Th | NM | 23,819.4 | - | |
| Avg. wages/employee | Rs Th | NM | 0 | - | |
| Avg. net profit/employee | Rs Th | NM | 646.8 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 1,255 | 833,681 | 0.2% | |
| Other income | Rs m | 370 | 0 | - | |
| Total revenues | Rs m | 1,625 | 833,681 | 0.2% | |
| Gross profit | Rs m | 111 | 215,726 | 0.1% | |
| Depreciation | Rs m | 38 | 156,098 | 0.0% | |
| Interest | Rs m | 2 | 40,097 | 0.0% | |
| Profit before tax | Rs m | 442 | 19,531 | 2.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1,212 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 24 | -3,107 | -0.8% | |
| Profit after tax | Rs m | 1,630 | 22,638 | 7.2% | |
| Gross profit margin | % | 8.9 | 25.9 | 34.2% | |
| Effective tax rate | % | 5.4 | -15.9 | -34.1% | |
| Net profit margin | % | 129.8 | 2.7 | 4,781.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 1,867 | 465,527 | 0.4% | |
| Current liabilities | Rs m | 591 | 339,420 | 0.2% | |
| Net working cap to sales | % | 101.6 | 15.1 | 672.0% | |
| Current ratio | x | 3.2 | 1.4 | 230.3% | |
| Inventory Days | Days | 94 | 84 | 112.8% | |
| Debtors Days | Days | 74 | 93 | 78.8% | |
| Net fixed assets | Rs m | 1,791 | 161,720 | 1.1% | |
| Share capital | Rs m | 534 | 444 | 120.3% | |
| Net worth | Rs m | 10,858 | 901,890 | 1.2% | |
| Long term debt | Rs m | 41 | 973,429 | 0.0% | |
| Total assets | Rs m | 11,591 | 2,419,220 | 0.5% | |
| Interest coverage | x | 260.9 | 1.5 | 17,543.2% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.4% | |
| Sales to assets ratio | x | 0.1 | 0.3 | 31.4% | |
| Return on assets | % | 14.1 | 2.6 | 542.8% | |
| Return on equity | % | 15.0 | 2.5 | 598.0% | |
| Return on capital | % | 15.2 | 3.2 | 477.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 236 | 173,239 | 0.1% | |
| From Investments | Rs m | -224 | -89,545 | 0.3% | |
| From Financial Activity | Rs m | -27 | -80,705 | 0.0% | |
| Net Cashflow | Rs m | -15 | 1,435 | -1.0% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.98 Rs / USD
Compare ALEMBIC With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ALEMBIC With: J.B.CHEMICALS ELDER PHARMA ALEMBIC PHARMA GSK PHARMA NATCO PHARMA
Today's Market
Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
Related Views On News
ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)
Aug 27, 2019 | Updated on Aug 27, 2019For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More
